Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

Published:2019 Issue:6 Volume:10 Page:1409-1416
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Zhang Xiaodong,Jia Jun,Lu Ming,Wang Xicheng,Gong Jifang,Li Jie,Li Jian,Li Yan,Zhang Xiaotian,Lu Zhihao,Zhou Jun,Yu Jing,Sun Zhiwei,Yang Ying,Liu Chuanling,Xiao Yanjie,Shen Lin

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study;CHINESE J CANCER RES;2024

2. Esophageal Squamous Cell Carcinoma;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

3. Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review;Current Oncology;2023-10-30

4. PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis;Journal of Immunotherapy;2022-04-26

5. Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma;Cancer Biology & Medicine;2022-01-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP